Cutler Group’s Denali Therapeutics DNLI Stock Holding History

Cutler Group’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,400	Closed	-$2K	–	4551
2022 Q3	$2K	Buy	+1,400	New	+$45.5K	﹤0.01%	4171
2022 Q2	–	Sell	-700	Closed	-$1K	–	5099
2022 Q1	$1K	Buy	+700	New	+$24.1K	﹤0.01%	4929
2021 Q4	–	Sell	-3,300	Closed	-$6K	–	5491
2021 Q3	$6K	Buy	3,300 +900	+38%	+$50.7K	﹤0.01%	4314
2021 Q2	$40K	Buy	2,400 +1,700	+243%	+$105K	﹤0.01%	2684
2021 Q1	$2K	Sell	700 -5,900	-89%	-$395K	﹤0.01%	4891
2020 Q4	$180K	Buy	6,600 +4,500	+214%	+$272K	0.01%	1142
2020 Q3	$9K	Buy	+2,100	New	+$63.2K	﹤0.01%	3058

Other funds holding DNLI

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

TPC

Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Cutler Group's DNLI Position: Q1 2024 in Review

Cutler Group held its Denali Therapeutics (DNLI) position steady in Q1 2024 at 400 shares worth $8K. The position accounts for ﹤0.01% of the portfolio, ranked #1367.

Cutler Group first reported a position in DNLI in Q4 2018 and has held it in 16 quarters since. The position peaked at $75K in Q4 2021. 210 funds tracked by Wall St. Rank hold DNLI as of Q1 2024.

Cutler Group held 400 shares of Denali Therapeutics worth $8K as of Q1 2024.
Cutler Group left its Denali Therapeutics share count unchanged in Q1 2024.
Denali Therapeutics made up ﹤0.01% of Cutler Group's portfolio in Q1 2024, its #1367 holding.
Cutler Group first reported a position in Denali Therapeutics in Q4 2018 and has held it in 16 quarters since.
Cutler Group's Denali Therapeutics position peaked at $75K in Q4 2021.
210 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.